{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP04122",
    "Peptide Name": "Lan-P49.2 (natural AMPs; nisin-like, lantibiotic, type 1, class 1 bacteriocin, Gram-positive bacteria, prokaryotes; UCSS1b; more AMPs?)",
    "Source": "Pseudobutyrivibrio sp. 49_2",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "ITSKSLCTPGCVTGVLMGCNNKTATCNCSVHVG",
    "Sequence Length": 33,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Anti-MRSA"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 3,
    "Boman Index": 0.4,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "42%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Discovery: applied RODEO to the public RefSeq database to identify novel nisin-like class I lantibiotics encoded in gut microbial genomes.Sequence analysis: APD analysis reveals that this sequence is similar (85.29%) toNisin QActivity:  Active against E. faecium ATCC700221 (MIC 10-100 uM), Methicillin-resistant S. aureus USA300 MRSA (MIC 10-100 uM), Methicillin-resistant S. epidermidis SK135 (MIC 10-100 uM), L. monocytogenes 10403S (MIC 10-100 uM), and C. difficile VPI10463 (MIC 1-10 uM), A. hadrus MSK.14.23 (MIC 0.01 uM), B. obeum MSK.18.40 (MIC 0.1 uM), B. luti MSK.20.18 (MIC 0.1 uM), E. ramosum MSK.23.96 (MIC 10 uM), D. formicogenerans MSK.17.61 (MIC 0.01-0.1 uM), C. comes MSK.11.23 (MIC 0.01 uM), C. eutactus MSK.18.32 (MIC 0.1-1 uM), and F. fissicatena MSK.9.3 (MIC 0.1 uM).Recombinant production:bacteria:Escherichia coli: expressed in E. coli followed by isolation and purification. Est.2024; 4/2024",
    "Author": "Zhang ZJ, Wu C, Moreira R, Dorantes D, Pappas T, Sundararajan A, Lin H, Pamer EG, van der Donk WA.2024",
    "Reference": "ACS Chem Biol. 2024 Jan 31. doi: 10.1021/acschembio.3c00577.PubMed",
    "Title": "Activity of Gut-Derived Nisin-like Lantibiotics against Human Gut Pathogens and Commensals."
  },
  "3D Structure": []
}